Cancer therapies such as immune checkpoint inhibitors, anthracyclines, and VEGF inhibitors exacerbate CKM-related complications, highlighting the need for multidisciplinary cardio-oncology teams to integrate CKM-specific risk stratification into oncology care. This evidence concerns the gene VEGFA and cancer.